A Multicenter Phase II Study of Docetaxel 60 mg/m2 as First-Line Chemotherapy in Patients with Advanced or Recurrent Breast Cancer

详细信息    查看全文

• 作者：Takashi Ishikawa (1)
  Satoru Shimizu (2)
  Masaaki Inaba (3)
  Taro Asaga (3)
  Kiyohumi Katayama (4)
  Mamoru Fukuda (5)
  Yutaka Tokuda (6)
  Kazuo Ishida (6)
  Eisuke Fukuma (7)
  Takashi Suda (8)
  Yohei Hamaguchi (9)
  Akira Ishiyama (10)
  Hiroshi Shimada (11)
  
• 关键词：Advanced breast cancer ; First ; line chemotherapy ; Docetaxel
• 刊名：Breast Cancer
• 出版年：2004
• 出版时间：November 2004
• 年：2004
• 卷：11
• 期：4
• 页码：374-379
• 全文大小：554KB
• 参考文献：1. Aapro MS: Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings. / Semin Oncol 26:17鈥?1, 1999.
  2. A鈥橦ern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type schedules. / Br J Cancer 67:801鈥?05, 1993.
  3. Early Breast Cancer Trialists鈥?Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. / Lancet 352:930鈥?42, 1998. CrossRef
  4. Crown J: A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer. / Semin Oncol 26:5鈥?, 1999.
  5. Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracyclineresistant or anthracenedione-resistant breast cancer. / J Clin Oncol 13:2879鈥?885, 1995.
  6. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. / J Clin Oncol 13:2886鈥?894, 1995.
  7. Sjostrom J, Mourisden H, Pluzanska A, Ottosson L, Bengtsson N-O, Ostenstad B: Taxotere (T) versus methotrexate-5-fluorouracil (MF) in patients with advanced anthracycline-resistant breast cancer: preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group. / Proc Am Soc Clin Oncol 17:111a (abtstr. 427), 1998.
  8. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian S: Docetaxel vs 5- fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. / Br J Cancer 18:1210鈥?215, 2002. CrossRef
  9. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, T. A. Vandenberg, B. Rapoport, R. Rosso, V. Trillet-Lenoir, J. Drbal, A. Molino, J.W.R. Nortier, D. J. Richel, T. Nagykalnai, P. Siedlecki, N. Wilking, J. Y. Genot, P.S.G.J. Hupperets, F. Pannuti, D. Skarlos, E. M. Tomiak, M. Murawsky, M. Alakl, A. Riva, M. Aapro, 304 Study Group. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. / J Clin Oncol 17:1413鈥?424, 1999.
  10. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E. Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. / J Clin Oncol 8:2341鈥?354, 1999.
  11. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. / J Clin Oncol 13:314鈥?22, 1995.
  12. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H: A multicentre phase II study of the efficacy and safety of docetaxel as firstline treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. / Ann Oncol 7:165鈥?71, 1996.
  13. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. / J Clin Oncol 14:58鈥?5, 1996.
  14. Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM: Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. / J Clin Oncol 14:422鈥?28, 1996.
  15. Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P: A multicentre phase II study of docetaxel 75 mg/m² as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. / Br J Cancer 74:650鈥?56, 1996.
  16. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M: Paclitaxel versus doxorubicin as first-line singleagent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. / J Clin Oncol 4:724鈥?33, 2000.
  17. Adachi I, Watanabe T, Takashima S, Narabayashi M, Horikoshi N, Aoyama H, Taguchi T: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. / Br J Cancer 73:210- 216, 1996.
  18. Ando M, Watanabe T, Nagata K, Narabayashi M, Adachi I, Katsumata N: Efficacy of docetaxel 60 mg/m² in patients with metastatic breast cancer according to the status of anthracycline resistance. / J Clin Oncol 19:336鈥?42, 2001.
  
• 作者单位：Takashi Ishikawa (1)
  Satoru Shimizu (2)
  Masaaki Inaba (3)
  Taro Asaga (3)
  Kiyohumi Katayama (4)
  Mamoru Fukuda (5)
  Yutaka Tokuda (6)
  Kazuo Ishida (6)
  Eisuke Fukuma (7)
  Takashi Suda (8)
  Yohei Hamaguchi (9)
  Akira Ishiyama (10)
  Hiroshi Shimada (11)
  
  1. Department of General Surgery, Yokohama City University Medical Center, 4-57, Urafunecho, 232-0024, Minami-ku, Yokohama, Japan
  2. Department of Surgery, Yokohama Minami Kyosai Hospital, Japan
  3. Department of Surgery, Breast and Thyroid Division, Kanagawa Cancer Center, Japan
  4. Department of Surgery, Hiratsuka Kyosai Hospital, Japan
  5. Department of Surgery, St. Marianna University School of Medicine, Japan
  6. Department of Surgery, School of Medicine, Tokai University, Japan
  7. Department of Breast Surgery, Kameda Medical Center, Japan
  8. Department of Surgery, Saiseikai Yokohama City Nanbu Hospital, Japan
  9. Department of Surgery, Yokosuka Kyosai Hospital, Japan
  10. Department of Surgery, Yokohama Municipal Citizen鈥檚 Hospital, Japan
  11. Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine, Japan
  

文摘

Purpose Docetaxel is an active agent as first-line chemotherapy in patients with advanced breast cancer at a dosage of 100 mg/m2. However, the efficacy of this agent as a first-line drug when used at a lower dosage is unclear. This study was performed to evaluate the clinical efficacy and safety of 60 mg/m2 docetaxel for the treatment of breast cancer. Patients and Methods This study enrolled 23 patients with advanced and/or metastatic breast cancer, who had not been treated with an anthracycline or taxane previously. Treatment with docetaxel was continued in patients showing a response until there was evidence of disease progression or unacceptable toxicity. Results Among 20 fully evaluated patients, the overall response rate was 50.0% and the median time to progression was 31 weeks. The most commonly observed adverse events were neutropenia (78.2%) and fatigue (60.9%). Fluid retention occurred in only 8.7% of the patients. Adverse events did not cause discontinuation of the treatment. Conclusion Docetaxel achieved good disease control with mild adverse events in first-line treatment at a dosage of 60 mg/m2.